Over the last 20 years, stem cells of varying origin and their associated secretome have been investigated as a therapeutic option for a myriad of neonatal models of disease, with very promising results. Despite the devastating nature of some of these disorders, translation of the preclinical evidence to the bedside has been slow. In this review, we explore the existing clinical evidence for stem cell therapies in neonates, highlight the barriers faced by researchers and suggest potential solutions to move the field forward.
Keywords: Barriers; Bronchopulmonary dysplasia (BPD); Cardiosphere Progenitor cells (CPC); Cerebral palsy (CP); Clinical research; Hypoxic ischemic Encephalopathy (HIE); Intraventricular hemorrhage (IVH); Mesenchymal Stem Cells (MSC); Necrotizing Enterocolitis (NEC); Neonatology; Prematurity; Stem cells (SC); Transamniotic stem cell therapy (TRASCET); Umbilical cord derived Mesenchymal stem cell (UC-MSC).
Copyright © 2023 Elsevier Inc. All rights reserved.